
A cannabis-based treatment was shown to be effective for cognitive disfunctions.
Europe is planning to host a multi-stakeholder workshop in April 2024 on medical psychedelics, where they plan to establish regulatory guidelines.
A new study looked into the possibilities of cannabis being used as a treatment in preventing and treating COVID-19, as well as Long-COVID.
A recently published observational study examined the risks of medical cannabis for developing various heart conditions.
Vetoed last year, the bill would allow dispensaries to sell non-cannabis products along with cannabis.
The HHS finds conclusive evidence for medical cannabis use and agreed with the FDA’s recommendation to reschedule cannabis as a Schedule III drug.
A plan for a medical cannabis program in Wisconsin was revealed earlier this week.
Cannabis legalization in Thailand takes a hit from new legislation which plans to ban recreational cannabis use.
The Attorney General recently drafted a bill to legalize recreational cannabis in the state and also provided the office’s position on the issue.
Ispire Technology Inc. recently obtained ISO certifications for their manufacturing facility located in Malaysia.
Healer’s first webinar of the year provided a research update on studies examining cannabis used as a treatment for different neurologic conditions.
The study tested how commercially-available cannabis products affect the experiences of exercising.
On January 10, 2024, the Connecticut for Accessible Psychedelic Medicine (CAPM) held an online and in person forum with lawmakers and experts in Hartford, Connecticut.
A recent study explored cannabinoids as an alternative treatment for neuropathic pain from spinal cord injuries.
Ziel secured their first GMP certification with their Radio Frequency technology for cannabis microbial control in the EU marketplace.
A new study involving veterans reported beneficial effects of ibogaine as a therapeutic treatment.
The UFC has officially removed cannabis from their banned substances list.
Researchers explored this complex relationship, highlighting the impacts and benefits.
Throughout 2023, Cannabis Science and Technology recorded various interviews on important topics in the cannabis industry, from live coverage at the Cannabis Science Conferences to innovations in technology and medical cannabis. Here we present our top 5 most-viewed interviews of the year—join us as we revisit the popular topics and insights from 2023 and get ready for more in 2024!
Late December 2023 saw another step in pardons for certain cannabis convictions.
Recently, California took matters into their own hands by shutting down most cannabis labs throughout the state.
A hold was placed in late December and is still under investigation.
Optimi Health recently received a Precursor License to import the precursor of MDMA and encapsulate the drug into specific dosages.
A recently proposed bipartisan bill would affect criminal charges surrounding cannabis possession in the Badger State.
Ascend Wellness Holdings, Inc., has opened a 4th cannabis dispensary location in Ohio.
Throughout 2023, Cannabis Science and Technology conducted various interviews with important figures in the cannabis industry, from researchers to cultivators to medical professionals and more. Here we present our top 10 most-viewed interviews of the year—catch up on information you may have missed and get a glimpse of the possibilities coming in 2024!
Our sister publication, Nutritional Outlook, recently published an article covering the year in CBD and looking ahead to what’s on the horizon in 2024.
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2023¬—including a lot of video interviews from the Cannabis Science Conference series. Here is just a small snippet of some of the top articles, columns, videos, blogs, and podcasts that our readers enjoyed. Click through and see if any of your favorites made the list!
Recreational cannabis is legal in some capacities, but Ohioans cannot yet buy it.
Missouri’s first holiday season is expected to affect cannabis sales in the state.